Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells

Cancer Research

Volumn 74, Issue 23, 2014, Pages 7115-7124

  Park, Ilwoo ^a   Mukherjee, Joydeep ^a,b   Ito, Motokazu ^a,b   Chaumeil, Myriam M ^a   Jalbert, Llewellyn E ^a   Gaensler, Karin ^b   Ronen, Sabrina M ^a   Nelson, Sarah J ^a   Pieper, Russell O ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; LACTATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PYRUVATE KINASE; PYRUVATE KINASE PKM2; PYRUVIC ACID; TEMOZOLOMIDE; UNCLASSIFIED DRUG; CARRIER PROTEIN; DACARBAZINE; MEMBRANE PROTEIN; METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN KINASE; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS; TUMOR MARKER;

AMINO ACID METABOLISM; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL GROWTH; CLONOGENESIS; CONTROLLED STUDY; DNA STRAND BREAKAGE; ENZYME ACTIVATION; ENZYME ACTIVITY; GLIOBLASTOMA CELL LINE; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; APOPTOSIS; DNA DAMAGE; DNA REPAIR; DRUG EFFECTS; GENE EXPRESSION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

APOPTOSIS; BIOMARKERS, TUMOR; CARRIER PROTEINS; CELL LINE, TUMOR; DACARBAZINE; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; L-LACTATE DEHYDROGENASE; MAGNETIC RESONANCE IMAGING; MEMBRANE PROTEINS; METHYLTRANSFERASES; NAD; PROTEIN KINASES; PYRUVIC ACID; THYROID HORMONES;

EID: 84918565322     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0849     Document Type: Article

References (50)

1. Osoba D, Braba M, Yung YKA, Prados MP. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000;18:1481-91.
2. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2011;106:35-43.
3. Margison GP, Santibanez Koref MF, Povey A. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002;17:483-7.
4. Karran P, Marinus MG. Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature 1982;296:868-9.
5. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. J Mol Pharm 1998;54:334-41.
6. Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001;61:1957-63.
7. Quiros S, Roos WP, Kaina B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 2010;9:168-78.
8. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G2 Checkpoint pathway potentiates Temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001;61:5843-9.
9. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 2003;23:8306-15.
10. Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from Temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res 2005;65:4861-9.
11. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, et al. Aselective inhibitor of the p100delta isoformof PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006;25:6648-59.
12. Venkatash HS, Chaumeil MM, Ward CS, Hass-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol 2012;14:315-25.
13. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
14. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
15. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfør K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000 60:916-21.
16. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011 71:6921-5.
17. Guminska M, Ignacak J, Kedryna M, Stachurska B. Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. Acta Biochim Pol 1997;44:711-24.
18. Kumar Y, Tapuria N, Kimani B, Davidson R. Tumor M2pyruvate kinase: a gastrointestinal cancer marker. Euro J Gastroenterol Hepatol 2007;19:265-76.
19. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature 2008;452:230-4.
20. Brindle K. New approaches for imaging tumor responses to treatment. Nat Rev Cancer 2008;8:94-107.
21. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nature Med 2007;13:1382-7.
22. Dafni H, Larson PEZ, Hu S, Yoshihara HAI, Ward CS, Venkatesh HS, et al. Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor. Cancer Res 2009;70:7400-10.
23. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, VanCriekinge M, Dafni H, et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res 2010;70:1296-305.
24. Chaumeil MM, Ozawa T, Park IW, Scotta K, James CD, Nelson SJ, et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroimage Volume 2012;59:193-201.
25. Hu S, Balakrishnan A, Bok RA, Anderton B, Larson PEZ, Nelson SJ, et al. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-myc-induced tumor formation and regression. Cell Metab 2011;14:131-42.
26. Park I, Larson P, Zierhut ML, Hu S, Bok R, Ozawa T, et al. Hyperpolarized 13C MR metabolic imaging: application to brain tumors. Neuro Oncol 2010;12:133-44.
27. Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, et al. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2013;70:33-9.
28. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, et al. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging 2011;33:1284-90.
29. Pegg AE, Wiest L, Foote RS, Mitra S, Perry W. Purification and properties of O6-methylguanine-DNA transmethylase from rat liver. J Biol Chem 1983;258:2327-33.
30. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BKA, Bigner SH, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 1997;57:2933-6.
31. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO. Early chk1 phosphorylation is driven by Temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS ONE 2013;8:e62351.
32. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is upregulated in a grade-specific manner in human glioma. PLoS ONE 2013;8:e57610.
33. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-21. Cancer Res 2001;61:6624-8.
34. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 2003;100:10158-63.
35. Derby K, Tropp J, Hawryszko C. Design and evaluation of a novel dual-tuned resonator for spectroscopic imaging. J Magn Reson 1990;86:645-51.
36. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med 2001;46:228-39.
37. Cunningham CH, Vigneron DB, Chen AP, Xu D, Nelson SJ, Hurd RE, et al. Design of flyback echo-planar readout gradients for magnetic resonance spectroscopic imaging. Magn Reson Med 2005;54:1286-9.
38. Brandes AH, Ward CS, Ronen SM. 17-allyamino-17-demethoxygel-danamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2. Breast Cancer Res 2010;12:R84.
39. Vassault A. Lactate dehydrogenase. UV-method with pyruvate and NADH. In:Bergmeyer HU, editor. Methods of enzymatic analysis. Weinheim: Verlag Chemie; 1983, p. 118-26.
40. Bernofsky C, Swan M. An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem 1973;53:452-8.
41. Dolan ME, Pegg AE. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997;3:837-47.
42. Langelier M-F, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 2012;336:728-32.
43. Witney TH, Kettunen MI, Hu D-E, Gallagher FA, Bohndiek SE, Napolitano F, et al. Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. Br J Cancer 2010;103:1400-6.
44. Yang W, Lu Z. Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett 2013;339:153-8.
45. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012;150:685-96.
46. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 2008;132:221-32.
47. Schilling F, Düwel S, Köllisch U, Durst M, Schulte RF, Glaser SJ, et al. Diffusion of hyperpolarized (13) C-metabolites in tumor cell spheroids using real-time NMR spectroscopy. NMR Biomed 2013;26:557-68.
48. Pfeuffer J, Lin JC, Delabarre L, Ugurbil K, Garwood M. Detection of intracellular lactate with localized diffusion {1H-13C}-spectroscopy in rat glioma in vivo. J Magn Reson 2005;177:129-38.
49. Hegi ME, Diserens A-C, Godard S, Dietrich P-Y, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
50. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343:189-93.